Published in Oncoimmunology on November 01, 2012
Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine (2013) 0.97
Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother (2014) 0.76
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol (2004) 8.65
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Migratory fate and differentiation of blood monocyte subsets. Immunobiology (2006) 4.30
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med (2006) 3.43
Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol (2009) 3.27
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer (2006) 3.05
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med (1990) 2.42
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 1.96
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood (2009) 1.95
Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res (1984) 1.91
Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol (2006) 1.77
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol (2007) 1.75
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res (2010) 1.72
In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (1981) 1.71
Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol (1989) 1.71
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res (2009) 1.64
A potential role for RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol (2009) 1.63
CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol (2010) 1.57
Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res (2007) 1.50
Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol (1999) 1.41
Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol (2005) 1.40
Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci (2010) 1.36
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood (2003) 1.35
Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia (2009) 1.33
Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest (2006) 1.29
Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci (2007) 1.28
HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res (2009) 1.24
Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci (2008) 1.18
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med (2005) 1.18
In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol (2010) 1.15
Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther (2008) 1.14
Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol (2009) 1.09
Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood (2002) 1.05
Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci (2006) 0.94
Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics (2010) 0.93
Functional alterations in CD11b(+)Gr-1(+) cells in mice injected with allogeneic tumor cells and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Int Immunopharmacol (2003) 0.88
Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. J Immunol (2010) 0.86
Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother (2009) 0.86
Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Exp Hematol (2006) 0.84
Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther (2006) 0.83
Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic against the tumor cells. Cancer Immunol Immunother (2009) 0.82
Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. Invest Ophthalmol Vis Sci (2010) 0.81
Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry. Angiogenesis (2010) 0.78
IgG antibodies to asialoGM1 are more sensitive than IgM antibodies to kill in vivo natural killer cells and prematured cytotoxic T lymphocytes of mouse spleen. Microbiol Immunol (1990) 0.77
Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol (2005) 2.79
Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 2.10
Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther (2010) 1.45
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Clinical evaluation of a single dose of immune plasma for treatment of canine parvovirus infection. J Am Vet Med Assoc (2012) 1.39
Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis (2009) 1.34
A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect Immun (2010) 1.26
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother (2010) 1.08
Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol (2013) 1.08
Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res (2006) 1.07
A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol (2006) 1.06
Early interaction of Yersinia pestis with APCs in the lung. J Immunol (2005) 0.98
Vaccine-induced CD8+ T cell-dependent suppression of airway hyperresponsiveness and inflammation. J Immunol (2009) 0.93
Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections. PLoS Pathog (2012) 0.93
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med (2007) 0.93
Suppression of vaccine immunity by inflammatory monocytes. J Immunol (2012) 0.91
Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine (2009) 0.91
Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther (2013) 0.90
In vitro comparison of feline bone marrow-derived and adipose tissue-derived mesenchymal stem cells. J Feline Med Surg (2012) 0.89
Consumption of rice bran increases mucosal immunoglobulin A concentrations and numbers of intestinal Lactobacillus spp. J Med Food (2012) 0.89
The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infect Immun (2011) 0.89
Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine melioidosis. PLoS Negl Trop Dis (2012) 0.88
Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes Infect (2010) 0.88
Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol Immunother (2009) 0.88
Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg (2011) 0.88
Immunoproteomic identification of bovine pericardium xenoantigens. Biomaterials (2008) 0.88
Dietary rice bran promotes resistance to Salmonella enterica serovar Typhimurium colonization in mice. BMC Microbiol (2012) 0.86
Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine (2012) 0.86
Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect Immun (2013) 0.86
Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol (2012) 0.85
Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol Immunother (2003) 0.85
Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther (2003) 0.83
Serum concentrations of monocyte chemoattractant protein-1 in healthy and critically ill dogs. Vet Clin Pathol (2010) 0.82
Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med (2006) 0.80
Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease. J Feline Med Surg (2012) 0.79
Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry. Angiogenesis (2010) 0.78
Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study. Vet Dermatol (2005) 0.78
Sustained generation of tissue dendritic cells from cats using organ stromal cell cultures. Vet Immunol Immunopathol (2007) 0.76
Evaluation of a novel immunotherapy for treatment of chronic rhinitis in cats. J Feline Med Surg (2006) 0.75